

# CITATION REPORT

List of articles citing

**Progressively impaired proteasomal capacity during terminal plasma cell differentiation**

**DOI: 10.1038/sj.emboj.7601009**  
**EMBO Journal, 2006, 25, 1104-13.**

**Source:** <https://exaly.com/paper-pdf/40446320/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
132	Ubiquitylation in normal and malignant hematopoiesis: novel therapeutic targets. <b>2006</b> , 20, 1511-8		14
131	ER storage diseases: a role for ERGIC-53 in controlling the formation and shape of Russell bodies. <i>Journal of Cell Science</i> , <b>2006</b> , 119, 2532-41	5.3	49
130	Conditions of endoplasmic reticulum stress favor the accumulation of cytosolic prion protein. <b>2006</b> , 281, 30431-8		80
129	Evidence that marginal zone B cells possess an enhanced secretory apparatus and exhibit superior secretory activity. <b>2006</b> , 177, 3791-8		36
128	Phospholipid biosynthesis program underlying membrane expansion during B-lymphocyte differentiation. <b>2007</b> , 282, 7591-605		65
127	Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. <b>2007</b> , 81, 13566-77		93
126	Bortezomib in the treatment of AL amyloidosis: targeted therapy?. <i>Haematologica</i> , <b>2007</b> , 92, 1302-7	6.6	78
125	The role of small molecule inhibitors for veterinary patients. <b>2007</b> , 37, 1121-36; vii		1
124	Managing and exploiting stress in the antibody factory. <b>2007</b> , 581, 3652-7		96
123	Proteasome inhibitors: antitumor effects and beyond. <b>2007</b> , 21, 30-6		192
122	Endoplasmic reticulum stress. <b>2007</b> , 1113, 58-71		112
121	Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. <b>2008</b> , 14, 195-203		40
120	SEL1L and HRD1 are involved in the degradation of unassembled secretory Ig-mu chains. <b>2008</b> , 215, 794-802		35
119	Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. <b>2008</b> , 38, 658-67		51
118	Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. <b>2008</b> , 141, 494-503		52
117	Building and operating an antibody factory: redox control during B to plasma cell terminal differentiation. <b>2008</b> , 1783, 578-88		38
116	Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. <b>2009</b> , 9, 201-9		251

115	The unfolded protein response of B-lymphocytes: PERK-independent development of antibody-secreting cells. <b>2008</b> , 45, 1035-43	103
114	Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. <b>2008</b> , 7, 2298-307	53
113	Ubiquitylation and cancer development. <b>2008</b> , 8, 118-23	11
112	Novel treatment strategies for antibody-mediated diseases: targeting long-lived plasma cells. <b>2008</b> , 3, 311-315	1
111	Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. <b>2009</b> , 11, 2317-31	103
110	Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. <b>2009</b> , 84, 268-72	38
109	Functional changes of human peripheral B-lymphocytes in pre-eclampsia. <b>2009</b> , 61, 313-21	16
108	Immunity and the regulation of protein synthesis: surprising connections. <b>2009</b> , 21, 70-7	14
107	[Depletion of plasma cells - a novel strategy in the therapy of systemic lupus erythematosus in mice and man]. <b>2009</b> , 68, 150-3	4
106	The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. <b>2009</b> , 113, 3040-9	192
105	Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. <b>2009</b> , 50, 974-84	50
104	The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. <b>2010</b> , 116, 3445-55	34
103	Proteasomes are not a target for doxorubicin in feline injection-site sarcoma. <b>2010</b> , 143, 164-72	1
102	Molecular chaperones and substrate ubiquitination control the efficiency of endoplasmic reticulum-associated degradation. <b>2010</b> , 12 Suppl 2, 32-8	26
101	Stressing the ubiquitin-proteasome system. <b>2010</b> , 85, 263-71	57
100	Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. <b>2010</b> , 77, 880-90	21
99	CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. <b>2010</b> , 47, 1356-65	51
98	Prolonged endoplasmic reticulum stress promotes mislocalization of immunoglobulins to the cytoplasm. <b>2010</b> , 47, 1719-27	10

97	Physiology and pathology of proteostasis in the early secretory compartment. <b>2010</b> , 21, 520-5		22
96	B- to plasma-cell terminal differentiation entails oxidative stress and profound reshaping of the antioxidant responses. <b>2010</b> , 13, 1133-44		82
95	A new fluorogenic peptide determines proteasome activity in single cells. <b>2010</b> , 53, 7452-60		15
94	Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. <b>2011</b> , 2011, 232037		64
93	Transplantation vs. conventional-dose therapy for amyloidosis. <b>2011</b> , 23, 214-20		29
92	Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. <b>2011</b> , 117, 542-52		81
91	Cellular stress response pathways and ageing: intricate molecular relationships. <i>EMBO Journal</i> , <b>2011</b> , 30, 2520-31	13	197
90	Proteostasis and plasma cell pathophysiology. <b>2011</b> , 23, 216-22		37
89	Proteome profiling suggests a pro-inflammatory role for plasma cells through release of high-mobility group box 1 protein. <b>2011</b> , 11, 1228-37		6
88	Clinical and investigational use of proteasome inhibitors for transplant rejection. <b>2011</b> , 20, 1535-42		11
87	Unfolded protein response in chronic obstructive pulmonary disease: smoking, aging and disease: a SAD trifecta. <b>2012</b> , 12, 883-98		17
86	Endoplasmic reticulum stress induces a caspase-dependent N-terminal cleavage of RBX1 protein in B cells. <b>2012</b> , 287, 31223-32		0
85	Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. <b>2012</b> , 188, 404-16		76
84	Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome?. <b>2012</b> , 27, 1698-701		4
83	Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma. <b>2012</b> , 420, 644-50		23
82	Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. <b>2012</b> , 92, 921-31		58
81	Molecular mechanisms of acquired proteasome inhibitor resistance. <b>2012</b> , 55, 10317-27		70
80	Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. <b>2012</b> , 49, 270-6		34

79	The proteasome in terminal plasma cell differentiation. <b>2012</b> , 49, 215-22		21
78	Proteasome inhibitors: an expanding army attacking a unique target. <b>2012</b> , 19, 99-115		409
77	Impact of genetic targets on cancer therapy. Forward. <b>2013</b> , 779, v-vi		1
76	A pH-regulated quality control cycle for surveillance of secretory protein assembly. <b>2013</b> , 50, 783-92		55
75	Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model. <b>2013</b> , 22, 742-7		8
74	Plasma cells require autophagy for sustainable immunoglobulin production. <b>2013</b> , 14, 298-305		284
73	Targeted therapy of multiple myeloma. <b>2013</b> , 779, 197-221		18
72	Mapping the crossroads of immune activation and cellular stress response pathways. <i>EMBO Journal</i> , <b>2013</b> , 32, 1214-24	13	96
71	Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome. <b>2013</b> , 40, 663-73		8
70	Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e74415	3-7	38
69	Autophagy in plasma cell pathophysiology. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 103	8.4	21
68	The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma. <b>2014</b> , 55, 1707-14		22
67	Autophagy, a new determinant of plasma cell differentiation and antibody responses. <b>2014</b> , 62, 289-95		27
66	Autophagy contributes to IL-17-induced plasma cell differentiation in experimental autoimmune myocarditis. <b>2014</b> , 18, 98-105		23
65	A RIDDle solved: why an intact IRE1/XBP-1 signaling relay is key for humoral immune responses. <b>2014</b> , 44, 641-5		4
64	Progressive quality control of secretory proteins in the early secretory compartment by ERp44. <i>Journal of Cell Science</i> , <b>2014</b> , 127, 4260-9	5-3	31
63	Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. <b>2014</b> , 18, 947-61		112
62	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. <b>2014</b> , 92, 61-70		16

61	Involvement of transcription factor XBP1s in the resistance of HDAC6 inhibitor Tubastatin A to superoxidation via acetylation-mediated proteasomal degradation. <b>2014</b> , 450, 433-9	7
60	Modulatory effects of bortezomib on host immune cell functions. <b>2015</b> , 7, 1011-22	41
59	Cap-Independent Translation in Hematological Malignancies. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 293	5:3 3
58	Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. <b>2015</b> , 2015, 172458	70
57	A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. <b>2015</b> , 11, 1161-78	67
56	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. <b>2015</b> , 18, 18-35	127
55	Proteasome inhibitors as experimental therapeutics of autoimmune diseases. <b>2015</b> , 17, 17	66
54	Refractory primary Sjögren syndrome successfully treated with bortezomib. <b>2015</b> , 21, 31-2	28
53	The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. <b>2015</b> , 290, 29854-68	55
52	Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. <b>2015</b> , 168, 14-25	27
51	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. <b>2016</b> , 29, 639-652	67
50	The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. <b>2016</b> , 9, 873-89	15
49	Stress Regulates Aquaporin-8 Permeability to Impact Cell Growth and Survival. <b>2016</b> , 24, 1031-44	62
48	The therapeutic potential of microbial proteasome inhibitors. <b>2016</b> , 37, 23-30	9
47	Proteasome inhibitors in cancer therapy. <b>2017</b> , 14, 417-433	437
46	The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. <b>2017</b> , 129, 2132-2142	55
45	SQSTM1/p62-mediated autophagy compensates for loss of proteasome polyubiquitin recruiting capacity. <b>2017</b> , 13, 1697-1708	60
44	Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis. <b>2017</b> , 7, 17626	6

43	Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. <b>2017</b> , 10,		29
42	Immunological memories of the bone marrow. <i>Immunological Reviews</i> , <b>2018</b> , 283, 86-98	11.3	48
41	Clogging the Ubiquitin-Proteasome Machinery with Marine Natural Products: Last Decade Update. <i>Marine Drugs</i> , <b>2018</b> , 16,	6	15
40	An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties. <b>2018</b> , 183, 102-113		5
39	Redox-Dependent Circuits Regulating B Lymphocyte Physiology. <b>2018</b> , 183-201		
38	Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome $\beta$ Subunit. <b>2019</b> , 14, 2005-2022		3
37	Contribution of Inhibition of Protein Catabolism in Myeloma. <b>2019</b> , 25, 11-18		6
36	Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. <i>Cancers</i> , <b>2019</b> , 11,	6.6	45
35	At the crossway of ER-stress and proinflammatory responses. <b>2019</b> , 286, 297-310		39
34	The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders. <b>2020</b> , 63, 1841-1858		18
33	Proteasome inhibition in multiple myeloma: lessons for other cancers. <b>2020</b> , 318, C451-C462		8
32	Multiple myeloma: the (r)evolution of current therapy and a glance into future. <i>Haematologica</i> , <b>2020</b> , 105, 2358-2367	6.6	21
31	Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives. <i>International Journal of Biological Sciences</i> , <b>2020</b> , 16, 2518-2526	11.2	1
30	Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 21588-21597	11.5	4
29	FAT10 localises in dendritic cell aggresome-like induced structures and contributes to their disassembly. <i>Journal of Cell Science</i> , <b>2020</b> , 133,	5.3	2
28	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 35-46	3.8	4
27	Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 231-242	2.3	1
26	Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 3883-3906	10.3	7

25	ER-phagy responses in yeast, plants, and mammalian cells and their crosstalk with UPR and ERAD. <i>Developmental Cell</i> , <b>2021</b> , 56, 949-966	10.2	22
24	B Cell Metabolism and Autophagy in Autoimmunity. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 681105	8.4	2
23	Plasma cell biology: Foundations for targeted therapeutic development in transplantation. <i>Immunological Reviews</i> , <b>2021</b> , 303, 168-186	11.3	1
22	The special unfolded protein response in plasma cells. <i>Immunological Reviews</i> , <b>2021</b> , 303, 35-51	11.3	2
21	Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms. <i>Marine Drugs</i> , <b>2021</b> , 19,	6	0
20	Cell Trafficking in Multiple Myeloma. <i>Open Journal of Hematology</i> , <b>2012</b> , 3,		8
19	Expression of mutant or cytosolic PrP in transgenic mice and cells is not associated with endoplasmic reticulum stress or proteasome dysfunction. <i>PLoS ONE</i> , <b>2011</b> , 6, e19339	3.7	27
18	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. <i>Cancers</i> , <b>2021</b> , 13,	6.6	12
17	Migration and Homing in Multiple Myeloma. <b>2013</b> , 215-239		
16	Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. <i>Oncotarget</i> , <b>2017</b> , 8, 113858-113873	3.3	
15	Overcoming drug resistance by targeting protein homeostasis in multiple myeloma.. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , <b>2021</b> , 4, 1028-1046	4.5	1
14	The concept of intrinsic versus extrinsic apoptosis.. <i>Biochemical Journal</i> , <b>2022</b> , 479, 357-384	3.8	4
13	Site-Specific Proteasome Inhibitors.. <i>Biomolecules</i> , <b>2021</b> , 12,	5.9	4
12	ER-phagy: mechanisms, regulation and diseases connected to the lysosomal clearance of the endoplasmic reticulum.. <i>Physiological Reviews</i> , <b>2022</b> ,	47.9	4
11	A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 203	9.8	1
10	Biogenesis of secretory immunoglobulin M requires intermediate non-native disulfide bonds and engagement of the protein disulfide isomerase ERp44.. <i>EMBO Journal</i> , <b>2021</b> , e108518	13	0
9	Laboratory-Based Rationale for Targeting the Protein Homeostasis Network in AL Amyloidosis. <i>Hemato</i> , <b>2022</b> , 3, 298-317	0.2	
8	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. <i>Frontiers in Oncology</i> , <b>2022</b> , 12,	5.3	1

- 7 A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax. **2022**, 12,
- 6 Integrated signaling and transcriptome analysis reveals Src-family kinase individualities and novel pathways controlled by their constitutive activity. ○
- 5 The dichotomous role of immunoproteasome in cancer: Friend or foe?. **2022**, ○
- 4 The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. **2022**, 13, 1
- 3 Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BIAJ mice. **2022**, 13, ○
- 2 The cellular biology of plasma cells: unmet challenges and opportunities. **2023**, ○
- 1 Effects of in vivo CXCR4 Blockade and Proteasome Inhibition on Bone Marrow Plasma Cells in HLA-Sensitized Kidney Transplant Candidates. **2023**, ○